Abstract:KEYWORDS: Respiratory viral infections have a major impact on human health and the newly approved vaccines for respiratory syncytial virus (RSV) are a welcomed addition for prevention of infection with this under appreciated pathogen. The recent SARS-CoV-2 (COVID-19) pandemic has, amongst many things, elevated awareness within medical communities and the general population about respiratory viral diseases, morbidity and mortality. In the lay community, viral respiratory diseases are often thought of as the 'cold' with symptoms of a sore throat, runny nose, achy muscles, cough, and perhaps fatigue. In medical communities, it has long since been known of the potential severe consequences of respiratory viral infections with influenza as an annual reminder of deaths, across all age groups, from severe disease and complications. A new reality of the COVID-19 pandemic, aside from severe acute infection and death, is the clinical phenomenon of 'long COVID' or persistence of recognized symptoms for prolonged periods after the acute infection has resolved. Originally long-COVID was thought to be a consequence of severe COVID in patients requiring hospitalization, however, more recently, long COVID has been reported from patients with milder disease (no hospitalization) but at a lessor frequency than seen from hospitalized patients [ Citation 1 ]. Persistent or complicated clinical consequences are also seen with other respiratory viruses and may include myocarditis or pericarditis, central nervous system involvement, pneumonia, and post-viral secondary bacterial infections. Specifically, Respiratory Syncytial Virus (RSV) infection may exacerbate chronic obstructive pulmonary disease, congestive heart failure and the virus may cause direct tissue damage – likely mediated by the inflammatory response [ Citation 2 ] – with long term impact. As such, 'long' health consequences from viral infection is not a COVID-19 only phenomena.

Respiratory viruses: Preventive and therapeutic approaches to diverse pathogens

Vaccines for Respiratory Viruses—COVID and Beyond

Immune Response to Respiratory Viral Infections

Respiratory viruses: New frontiers-a Keystone Symposia report

Recent Advances in Respiratory Immunization: A Focus on COVID-19 Vaccines

Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

Inflammatory response to SARS-CoV 2 and other respiratory viruses

Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell

Respiratory Virus and COVID-19

The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins

Immunity towards human respiratory syncytial virus

Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches

Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus

Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives

Current Insights into the Host Immune Response to Respiratory Viral Infections

An Overview of Respiratory Syncytial Virus Vaccine Development

Prevention of SARS-CoV-2 and respiratory viral infections in healthcare settings: current and emerging concepts

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

So we now have RSV vaccines. What's our next steps?